Bangladesh Pharmaceuticals & Healthcare Report Q2 2016 - New Report Available

While Bangladesh's ambitious goals for pharmaceutical exports are unlikely to be realised, the sector will see modest growth ahead. Emerging markets such as Myanmar will be stable sources of demand even as opportunities to export to the lucrative developed markets such as the US and the EU grow due to cost containment. A key risk to this stems from the commoditisation of the generic drug sector, which will place pressure on profit margins, and the competition from the more established Indian pharmaceutical sector.

Headline Expenditure Projections

Pharmaceuticals: BDT171.6bn (USD2.2bn) in 2015 to BDT190.8bn (USD2.4bn) in 2016; +11.2% in local currency terms and +9.1% in US dollar terms.
Healthcare: BDT494.0bn (USD6.3bn) in 2015 to BDT554.9bn (USD7.0bn) in 2016; +12.3% in local currency terms and +10.3% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1130872_bangladesh_pharmaceuticals.aspx?afid=301

Risk/Reward Index

In Q216 Bangladesh's Risk/Reward Index (RRI) score remains unchanged from last quarter at 41.8 out of 100. Bangladesh also retains its ranking position in BMI's RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Latest Updates

February 2016

In February 2016, the Bangladesh Minister of Health noted that the country is at risk of a spread of swine flu following an outbreak in India.

February also saw calls by health rights groups to implement strong regulations governing the private sector. Acknowledging the shortcomings in the sector, authorities have noted that they intend to update their monitoring mechanism.

In January 2016, The Export Promotion Bureau (EPB) reporting in January 2016 that medicine exports for the first six months of FY2015/16 (July 2015 to December 2015) amounted to BDT3bn (USD38mn). According to the EPB, this amount was 18% higher than the same period last year.

BMI Economic View

Bangladesh's economy will likely grow by 6.5% in FY2015/16 (July-June), similar to the rate in FY2014/15, on the back of robust expansions in the industrial and services sectors. However, the global economic slowdown and domestic security threats pose downside risks to our optimistic view.

BMI Political View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Oman Pharmaceuticals & Healthcare Report Q2 2016
- Iraq Pharmaceuticals & Healthcare Report Q2 2016
- Estonia Pharmaceuticals & Healthcare Report Q2 2016
- Latvia Pharmaceuticals & Healthcare Report Q2 2016
- Egypt Pharmaceuticals & Healthcare Report Q2 2016